Klinikte Myleran Tedavisinden Elde Edilen Neticeler

Year 1961, Volume: 14 Issue: 3, 101 - 109, 30.09.1961

Fevzi Renda

Abstract

During the years 1957-1960, on 19 patients who were diagnosed as having chronic myeloid leukemia myleran was administered at the Second Medical Department of Ankara Medical School.

Remission was observed in 15 of these cases following myleran therapy. In 3 of the patients no significant improvement was observed in spite of one month's myleran therapy, and in fact, these three showed acute exacerbation of their illnesses and died while under such therapy. As thrombocytopenia was observed in one case immediately after institution of myleran therapy, the drug was discontinued.

The results obtained in this study suggest that myleran is an effective and safe drug for the treatment of chronic myeloid leukemia.

Keywords

Myleran, chronic myeloid leukemia, chemotherapy

Ethical Statement

-

Supporting Institution

Ankara University Faculty of Medicine Internal Medicine Clinic

Project Number

-

Thanks

-

Longterm Myleran Therapy in Chronic Myeloid Leukemia

Abstract

1957-1960 yılları arasında A. Ü. Tıp Fakültesi İkinci İç Hastalıkları Kliniğinde yatarak tedavi edilen 19 kronik miyeloid lösemi vak'asında myleran tatbik edilmiştir. 15 vak'ada myleran tedavisini müteakip hastalarda klinik bir salah müşahede edilmiştir. 3 vak'ada myleran'ın asgari birer aylık süre ile tatbikine rağmen hissedilir bir salah tesbit edilmemiş ve bilâkis bu hastalar akut birer hecme göstererek myleran tedavisi altında iken vefat etmişlerdir. Bir vak'ada ise myleran tatbikinden kısa bir zaman sonra trombositopeni müşahede edildiğinden tedaviye son verilmiştir.

Elde edilen neticeler, myleran'ın kronik miyeloid lösemi tedavisinde emin ve müessir bir ilâç olabileceğini düşündürmektedir.

Keywords

Myleran, kronik miyeloid lösemi, kemoterapi

Ethical Statement

-

Supporting Institution

Ankara Üniversitesi Tıp Fakültesi İç Hastalıkları Kliniği

Project Number

-

Thanks

-

References

• 1 — Haddow, A., and Timms, G. M.: Myleran in chronic myeloid leukaemia. Chemical constitution and biological action. Lancet, 1: 207, 1953.
• 2 — Galton, D. A. G.: Myleran in chronic myeloid leukaemia. Lancet, 1: 208, 1953.
• 3 — Galton, D. A. G., and Till, M.: Myleran in chronic myeloid leukaemia. Lancet, 1: 425, 1955.
• 4 — Petrakis, N. L., Bierman, H. R., Kelly, K. H., White, L. P. and Shimkin, M. B.: The effect of 1,4-dimethanesulfonyloxybutane (GT-41 or Myleran) upon leukaemia. Cancer, 7: 383, 1954.
• 5 — Di Pietro, S. and Gallico, E.: Remission temporaire inattendue par le 1,4-dimethylsulfenyl-oxybutane (Myleran) dans un cas de leucemie myeloide en pousse hemocytoblastique. Sang, 26: 434, 1955.
• 6 — Frost, J. W. and Jackson, C. B.: Myleran in the treatment of chronic granulocytic leukaemia. J. Amer. Med. Ass., 161: 54, 1956.
• 7 — Galton, D. A. G., Till, M. and Wiltshaw, E.: Busulfan (1,4-dimethanesulphonyloxybutane, Myleran): Summary of clinical results. Ann. N. Y. Acad. Sci., 69: 967, 1958.
• 8 — Fornner, C. E. and Scott, T. F. M.: Arsenic as a therapeutic agent in chronic Myelogenous leukaemia. Jour. Am. Med. Ass., 97: 3, 1931.
• 9 — Kalapos, I.: Die wirkung des benzols bei der leukamie, Klin. Wschr. 14: 861, 1935.
• 10 — Paterson, E., Haddow, A., Ap Thomas, I. and Watkinson, J. M.: Leukaemia treated with Urethane compared with deep X-ray therapy. Lancet, 1: 677, 1946.
• 11 — Karnofsky, D. A.: Triethylene Melamine in the treatment of lymphomas and leukaemias. M. Clin. North America, 38: 541, 1954.
• 12 — Reinhard, E. H., Moore, C. V., BİERBAUM, O. S. and Moore, S.: Radioactive phosphorus as a therapeutic agent. Jour. Lab. and Clin. Med. 31: 107, 1946.